Zycolchin 0.5mg Tablet

Zycolchin contains colchicine, which is used to reduce the inflammation associated with gout. Current product information and colchicine references support these uses:

• Acute gout: Helps reduce inflammation and symptoms during a gout flare.

• Gout-flare prevention: Can be prescribed when starting medicines such as allopurinol or other urate-lowering treatment.

• Inflammatory control: Colchicine acts on the inflammatory response rather than directly lowering blood uric acid.

• In the United States, colchicine is also an approved treatment for familial Mediterranean fever (FMF), but U.S. labeling uses different strengths and regimens; this should not be assumed to be a Zycolchin-specific indication.

Colchicine works inside inflammatory cells by interfering with microtubules, structures needed for cell movement and activity. This reduces the migration and activation of neutrophils around urate crystals deposited in a joint. As a result, the inflammatory response responsible for gout pain, swelling and tenderness is reduced.

Unlike allopurinol or febuxostat, colchicine does not reduce uric acid production or remove existing urate deposits. It is therefore generally used to control or prevent inflammatory flares rather than as the sole long-term treatment for high uric acid.

The correct colchicine regimen depends on the indication, age, kidney and liver function, other medicines and the specific product instructions. Do not use the following as an individual prescription.

Situation	General reference for 500-microgram colchicine
Acute gout	A current UK 500-microgram SmPC describes 1 mg initially, followed by 0.5 mg after 1 hour
Further treatment	No additional dose for 12 hours; subsequent dosing must follow the prescribed regimen
Gout-flare prophylaxis	A current UK SmPC lists 0.5–1 mg daily when starting urate-lowering treatment
Maximum course	The cited UK SmPC limits an acute course to 6 mg

Swallow tablets with water and follow the exact instructions supplied by the prescriber or dispensing pharmacist. Colchicine doses must not be taken closer together simply because symptoms continue.

Colchicine is particularly sensitive to medicines that increase its concentration in the body. Before using Zycolchin, provide your doctor or pharmacist with a complete medication list.

• Important interacting medicines include clarithromycin and erythromycin, some antifungals, ciclosporin, certain HIV medicines, verapamil and diltiazem.

• Grapefruit or grapefruit juice can increase colchicine exposure and should generally be avoided unless a healthcare professional confirms it is appropriate.

• Some statins and fibrates can increase the risk of muscle toxicity when combined with colchicine.

• Kidney or liver impairment can increase the risk of colchicine accumulation and may require a different regimen.

• Never increase, repeat or extend colchicine treatment without professional advice.

The most common adverse effects are gastrointestinal and may include:

• Diarrhoea

• Nausea or vomiting

• Abdominal pain or cramping

• Gastrointestinal irritation

Persistent or severe gastrointestinal symptoms can be an early warning of colchicine toxicity rather than an effect to simply tolerate. More serious reactions can include bone-marrow suppression, muscle injury, nerve problems, liver injury and kidney damage. Seek urgent medical attention for severe weakness or muscle pain, unusual bruising or bleeding, fever or sore throat, marked gastrointestinal symptoms, or symptoms following an accidental overdose.

Colchicine has a narrow therapeutic range, meaning the difference between an appropriate dose and a toxic dose can be small. Fatal overdoses have been reported. Never take more tablets than prescribed or repeat a gout course earlier than instructed.

Extra caution is required in people with kidney or liver disease, blood disorders, cardiovascular or gastrointestinal disease, and in older or debilitated patients. Colchicine can cause serious blood-cell abnormalities and neuromuscular toxicity. The risk is particularly important when it is combined with strong CYP3A4 or P-glycoprotein inhibitors; some combinations are contraindicated in patients with renal or hepatic impairment.

Tell your healthcare professional if you are pregnant, planning pregnancy or breastfeeding. Pregnancy decisions may depend on the reason colchicine is being used. Keep tablets securely away from children because accidental ingestion can be extremely dangerous. Store the medicine according to the product packaging and dispose of unused tablets according to local requirements.

This information is for general education and does not replace advice from a doctor, pharmacist or qualified healthcare professional.